Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Lung Cancer

  Free Subscription


02.04.2018

1 AJR Am J Roentgenol
1 Am J Ind Med
1 Am J Respir Crit Care Med
1 Ann Surg Oncol
2 Ann Thorac Surg
7 Anticancer Res
1 Arch Pathol Lab Med
3 BMC Cancer
2 Cancer
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
1 Cancer Sci
1 Clin Cancer Res
1 Clin Lung Cancer
1 Eur J Cancer
1 Eur J Cardiothorac Surg
1 Int J Cancer
2 Int J Oncol
2 J Clin Oncol
2 J Surg Oncol
2 J Thorac Cardiovasc Surg
14 J Thorac Oncol
13 Lung Cancer
1 Lung Cancer (Auckl)
4 N Engl J Med
1 Oncogene
1 Oncologist
2 PLoS One
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. GARCIA-GARRIGOS E, Arenas-Jimenez JJ, Sanchez-Paya J
    Best Protocol for Combined Contrast-Enhanced Thoracic and Abdominal CT for Lung Cancer: A Single-Institution Randomized Crossover Clinical Trial.
    AJR Am J Roentgenol. 2018 Mar 23:1-9. doi: 10.2214/AJR.17.19185.
    PubMed     Text format     Abstract available


    Am J Ind Med

  2. RICHARDSON DB, Keil AP, Cole SR, Dement J, et al
    Asbestos standards: Impact of currently uncounted chrysotile asbestos fibers on lifetime lung cancer risk.
    Am J Ind Med. 2018 Mar 24. doi: 10.1002/ajim.22836.
    PubMed     Text format     Abstract available


    Am J Respir Crit Care Med

  3. SALEHI-RAD R, Dubinett SM
    Understanding the Hurdles in Lung Cancer Immunotherapy in the Context of Chronic Obstructive Pulmonary Disease.
    Am J Respir Crit Care Med. 2018 Mar 28. doi: 10.1164/rccm.201803-0523.
    PubMed     Text format    


    Ann Surg Oncol

  4. KRANTZ SB
    Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base.
    Ann Surg Oncol. 2018 Mar 26. pii: 10.1245/s10434-018-6441.
    PubMed     Text format    


    Ann Thorac Surg

  5. SUBRAMANIAN M, McMurry T, Meyers BF, Puri V, et al
    Long-Term Results for Clinical Stage IA Lung Cancer- Comparing Lobectomy and Sublobar Resection.
    Ann Thorac Surg. 2018 Mar 23. pii: S0003-4975(18)30387.
    PubMed     Text format     Abstract available

  6. TURNER SR, Seyednejad N, Nasir BS
    Patterns of Practice in Mediastinal Lymph Node Staging for Non-Small Cell Lung Cancer in Canada.
    Ann Thorac Surg. 2018 Mar 26. pii: S0003-4975(18)30392.
    PubMed     Text format     Abstract available


    Anticancer Res

  7. KANAJI N, Yokohira M, Watanabe N, Kadowaki N, et al
    Transforming Growth Factor-Beta Produced by Non-small Cell Lung Cancer Cells Contributes to Lung Fibroblast Contractile Phenotype.
    Anticancer Res. 2018;38:2007-2014.
    PubMed     Text format     Abstract available

  8. HSIA TC, Huang YP, Jiang YW, Chen HY, et al
    Phenethyl Isothiocyanate Induces Apoptotic Cell Death Through the Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro.
    Anticancer Res. 2018;38:2137-2147.
    PubMed     Text format     Abstract available

  9. BIANCONI F, Fravolini ML, Bello-Cerezo R, Minestrini M, et al
    Evaluation of Shape and Textural Features from CT as Prognostic Biomarkers in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2155-2160.
    PubMed     Text format     Abstract available

  10. CHEN WT, Chen YK, Lin SS, Hsu FT, et al
    Hyperforin Suppresses Tumor Growth and NF-kappaB-mediated Anti-apoptotic and Invasive Potential of Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2161-2167.
    PubMed     Text format     Abstract available

  11. LUND-IVERSEN M, Scott H, Strom EH, Theiss N, et al
    Expression of Estrogen Receptor-alpha and Survival in Advanced-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2261-2269.
    PubMed     Text format     Abstract available

  12. TAKEMURA Y, Chihara Y, Morimoto Y, Tanimura K, et al
    Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2385-2390.
    PubMed     Text format     Abstract available

  13. VO VTA, Choi JW, Phan ANH, Hua TNM, et al
    TRAP1 Inhibition Increases Glutamine Synthetase Activity in Glutamine Auxotrophic Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:2187-2193.
    PubMed     Text format     Abstract available


    Arch Pathol Lab Med

  14. AISNER DL
    The Revised College of American Pathologists/International Association for the Study of Lung Cancer Guidelines/Association for Molecular Pathology: A Step Forward for Molecular Cytopathology.
    Arch Pathol Lab Med. 2018 Mar 29. doi: 10.5858/arpa.2018-0081.
    PubMed     Text format    


    BMC Cancer

  15. TAN PT, Aziz MIA, Pearce F, Lim WT, et al
    Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    BMC Cancer. 2018;18:352.
    PubMed     Text format     Abstract available

  16. RADWAN N, Phillips R, Ross A, Rowe SP, et al
    A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    BMC Cancer. 2017;17:453.
    PubMed     Text format     Abstract available

  17. BRUECKL WM, Achenbach HJ, Ficker JH, Schuette W, et al
    Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
    BMC Cancer. 2018;18:333.
    PubMed     Text format     Abstract available


    Cancer

  18. PRINTZ C
    Lung cancer screening based on personal risk may save more lives.
    Cancer. 2018;124:1315.
    PubMed     Text format    

  19. HIRSCH FR, Sequist LV, Gore I, Mooradian M, et al
    Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31313.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  20. ROSS K, Kramer MR, Jemal A
    Geographic Inequalities in Progress against Lung Cancer among Women in the United States, 1990-2015.
    Cancer Epidemiol Biomarkers Prev. 2018 Mar 30. pii: 1055-9965.EPI-17-0934.
    PubMed     Text format     Abstract available


    Cancer Lett

  21. LE HT, Nguyen HT, Min HY, Hyun SY, et al
    Corrigendum to "Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells" [Canc. Lett. 412 (2018) 297-307].
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30220.
    PubMed     Text format    


    Cancer Sci

  22. WANG N, Song X, Liu L, Niu L, et al
    Circulating exosomes contain protein biomarkers of metastatic non-small-cell lung cancer.
    Cancer Sci. 2018 Mar 23. doi: 10.1111/cas.13581.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  23. MCCOACH CE, Blakely CM, Banks KC, Levy BM, et al
    Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-2588.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  24. NADLER E, Espirito JL, Pavilack M, Boyd M, et al
    Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
    Clin Lung Cancer. 2018 Feb 17. pii: S1525-7304(18)30021.
    PubMed     Text format     Abstract available


    Eur J Cancer

  25. DALL'OLIO FG, Brocchi S, Massucci M, Sperandi F, et al
    Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?
    Eur J Cancer. 2018 Mar 21. pii: S0959-8049(18)30227.
    PubMed     Text format    


    Eur J Cardiothorac Surg

  26. PAN X, Gu C, Yang J, Shi J, et al
    Robotic double-sleeve resection of lung cancer: technical aspects.
    Eur J Cardiothorac Surg. 2018 Mar 20. pii: 4944680. doi: 10.1093.
    PubMed     Text format     Abstract available


    Int J Cancer

  27. HYNDS RE, Ben Aissa A, Gowers KHC, Watkins TBK, et al
    Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors.
    Int J Cancer. 2018 Mar 22. doi: 10.1002/ijc.31383.
    PubMed     Text format     Abstract available


    Int J Oncol

  28. MARUOKA T, Kitanaka A, Kubota Y, Yamaoka G, et al
    Lemongrass essential oil and citral inhibit Src/Stat3 activity and suppress the proliferation/survival of small-cell lung cancer cells, alone or in combination with chemotherapeutic agents.
    Int J Oncol. 2018 Mar 13. doi: 10.3892/ijo.2018.4314.
    PubMed     Text format     Abstract available

  29. ZHANG L, Lu J, Zhou H, Du Z, et al
    Silencing of aquaporin 5 inhibits the growth of A549 lung cancer cells in vitro and in vivo.
    Int J Oncol. 2018 Mar 16. doi: 10.3892/ijo.2018.4326.
    PubMed     Text format     Abstract available


    J Clin Oncol

  30. WU YL, Yang JC, Kim DW, Lu S, et al
    Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2018 Mar 29:JCO2017755587. doi: 10.1200/JCO.2017.75.5587.
    PubMed     Text format     Abstract available

  31. GETTINGER S, Horn L, Jackman D, Spigel D, et al
    Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
    J Clin Oncol. 2018 Mar 23:JCO2017770412. doi: 10.1200/JCO.2017.77.0412.
    PubMed     Text format     Abstract available


    J Surg Oncol

  32. COLLAUD S, Provost B, Besse B, Fabre D, et al
    Should surgery be part of the multimodality treatment for stage IIIB non-small cell lung cancer?
    J Surg Oncol. 2018 Mar 24. doi: 10.1002/jso.25042.
    PubMed     Text format     Abstract available

  33. SON BY, Cho S, Yum SW, Kim K, et al
    The maximum standardized uptake value of preoperative positron emission tomography/computed tomography in lung adenocarcinoma with a ground-glass opacity component of less than 30 mm.
    J Surg Oncol. 2018;117:451-456.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  34. ROCCO G
    Every breath you take: The value of the electronic nose (e-nose) technology in the early detection of lung cancer.
    J Thorac Cardiovasc Surg. 2018 Mar 2. pii: S0022-5223(18)30604.
    PubMed     Text format    

  35. SU K, Gao S, Ying J, Zou S, et al
    Sequencing a super multiple synchronous lung cancer reveals a novel variant in driver gene ARID1B.
    J Thorac Cardiovasc Surg. 2018 Mar 6. pii: S0022-5223(18)30059.
    PubMed     Text format    


    J Thorac Oncol

  36. LI Y, Liu B, Connolly ID, Kakusa BW, et al
    Brief Report: Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
    J Thorac Oncol. 2018 Mar 28. pii: S1556-0864(18)30222.
    PubMed     Text format     Abstract available

  37. SHIBAHARA D, Tanaka K, Iwama E, Kubo N, et al
    Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Mar 26. pii: S1556-0864(18)30215.
    PubMed     Text format     Abstract available

  38. LEE CK, Lord S, Marschner I, Wu YL, et al
    The value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer.
    J Thorac Oncol. 2018 Mar 23. pii: S1556-0864(18)30212.
    PubMed     Text format     Abstract available

  39. FLORES R, Taioli E, Yankelevitz DF, Becker BJ, et al
    Initiative for Early Lung Cancer Research on Treatment: Development of Study Design and Pilot Implementation.
    J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30211.
    PubMed     Text format     Abstract available

  40. GETTINGER SN, Wurtz A, Goldberg SB, Rimm D, et al
    Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in Twenty-Six Patients with Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30210.
    PubMed     Text format     Abstract available

  41. WATANABE J, Furuya N, Fujiwara Y
    Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.
    J Thorac Oncol. 2018;13:e66-e69.
    PubMed     Text format    

  42. MORMILE R
    Metformin and Lung Cancer: The Final Blow to the Obesity Paradox?
    J Thorac Oncol. 2018;13:e65-e66.
    PubMed     Text format    

  43. SAFIRI S
    Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity.
    J Thorac Oncol. 2018;13:e61.
    PubMed     Text format    

  44. MASAI K, Motoi N
    Response to Letter to the Editor Titled "Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer".
    J Thorac Oncol. 2018;13:e58-e59.
    PubMed     Text format    

  45. MANSORI K, Ayubi E, Safiri S
    Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer.
    J Thorac Oncol. 2018;13:e57-e58.
    PubMed     Text format    

  46. SUN JM
    Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer".
    J Thorac Oncol. 2018;13:e56-e57.
    PubMed     Text format    

  47. LEVY A, Hendriks LE, Faivre-Finn C
    Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?
    J Thorac Oncol. 2018;13:475-477.
    PubMed     Text format    

  48. SANDFELD-PAULSEN B, Aggerholm-Pedersen N
    Response to Safri: "Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity".
    J Thorac Oncol. 2018;13:e61-e62.
    PubMed     Text format    

  49. COSTANTINI A, Cadranel J
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e55-e56.
    PubMed     Text format    


    Lung Cancer

  50. SAKAKURA N, Mizuno T, Kuroda H, Arimura T, et al
    The eighth TNM classification system for lung cancer: A consideration based on the degree of pleural invasion and involved neighboring structures.
    Lung Cancer. 2018;118:134-138.
    PubMed     Text format     Abstract available

  51. HUDSON A, Chan C, Woolf D, McWilliam A, et al
    Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?
    Lung Cancer. 2018;118:139-147.
    PubMed     Text format     Abstract available

  52. HELFRICH BA, Gao D, Bunn PA Jr
    Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
    Lung Cancer. 2018;118:148-154.
    PubMed     Text format     Abstract available

  53. COUNAGO F, Rodriguez de Dios N, Montemuino S, Jove-Teixido J, et al
    Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Lung Cancer. 2018;118:119-127.
    PubMed     Text format     Abstract available

  54. BAINE MJ, Verma V, Schonewolf CA, Lin C, et al
    Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Lung Cancer. 2018;118:20-26.
    PubMed     Text format     Abstract available

  55. LEE JW, Choi JS, Lyu J, Lee SM, et al
    Prognostic significance of (18)F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer.
    Lung Cancer. 2018;118:41-47.
    PubMed     Text format     Abstract available

  56. SONG Z, Cheng G, Xu C, Wang W, et al
    Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:57-61.
    PubMed     Text format     Abstract available

  57. HAINSWORTH JD, Waterhouse DM, Shih KC, Boccia RV, et al
    Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
    Lung Cancer. 2018;118:6-12.
    PubMed     Text format     Abstract available

  58. LIAO WY, Ho CC, Tsai TH, Chen KY, et al
    Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Lung Cancer. 2018;118:90-96.
    PubMed     Text format     Abstract available

  59. IMAI S, Kobayashi M, Takasaki C, Ishibashi H, et al
    High expression of P-cadherin is significantly associated with poor prognosis in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:13-19.
    PubMed     Text format     Abstract available

  60. FILIPSKA M, Skrzypski M, Czetyrbok K, Stokowy T, et al
    MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.
    Lung Cancer. 2018;118:111-118.
    PubMed     Text format     Abstract available

  61. LIU Y, Li Y, Ou Q, Wu X, et al
    Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Lung Cancer. 2018;118:1-5.
    PubMed     Text format     Abstract available

  62. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
    Lung Cancer. 2018 Mar 19. pii: S0169-5002(18)30301.
    PubMed     Text format    


    Lung Cancer (Auckl)

  63. DONOVAN EK, Swaminath A
    Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives.
    Lung Cancer (Auckl). 2018;9:13-23.
    PubMed     Text format     Abstract available


    N Engl J Med


  64. Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261-1263.
    PubMed     Text format    

  65. WARD MC, Prabhu RS, Burri SH
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261.
    PubMed     Text format    

  66. ROCA E, Amoroso V, Berruti A
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261-2.
    PubMed     Text format    

  67. CHOI JY, Choi YJ, Shin SW
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1262.
    PubMed     Text format    


    Oncogene

  68. MONTERISI S, Riso PL, Russo K, Bertalot G, et al
    HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype.
    Oncogene. 2018 Mar 26. pii: 10.1038/s41388-018-0229.
    PubMed     Text format     Abstract available


    Oncologist

  69. SAROCCHI M, Grossi F, Arboscello E, Bellodi A, et al
    Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
    Oncologist. 2018 Mar 22. pii: theoncologist.2017-0452.
    PubMed     Text format     Abstract available


    PLoS One

  70. KIM CR, Kim EY, Kim YS, Ahn HK, et al
    Histologic subtypes are not associated with the presence of sarcopenia in lung cancer.
    PLoS One. 2018;13:e0194626.
    PubMed     Text format     Abstract available

  71. CHEN CH, Chang CK, Tu CY, Liao WC, et al
    Radiomic features analysis in computed tomography images of lung nodule classification.
    PLoS One. 2018;13:e0192002.
    PubMed     Text format     Abstract available


    Thorax

  72. SCHREUDER A, Schaefer-Prokop CM, Scholten ET, Jacobs C, et al
    Lung cancer risk to personalise annual and biennial follow-up computed tomography screening.
    Thorax. 2018 Mar 30. pii: thoraxjnl-2017-211107.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: